WO2010058860A1 - Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon - Google Patents

Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon Download PDF

Info

Publication number
WO2010058860A1
WO2010058860A1 PCT/JP2009/069898 JP2009069898W WO2010058860A1 WO 2010058860 A1 WO2010058860 A1 WO 2010058860A1 JP 2009069898 W JP2009069898 W JP 2009069898W WO 2010058860 A1 WO2010058860 A1 WO 2010058860A1
Authority
WO
WIPO (PCT)
Prior art keywords
crp
antibody
reagent
sample
binds
Prior art date
Application number
PCT/JP2009/069898
Other languages
English (en)
Japanese (ja)
Inventor
穴田哲也
中村雄樹
Original Assignee
株式会社シノテスト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社シノテスト filed Critical 株式会社シノテスト
Priority to JP2010539268A priority Critical patent/JP5807300B2/ja
Publication of WO2010058860A1 publication Critical patent/WO2010058860A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein

Definitions

  • the present invention relates to a method and reagent for measuring C-reactive protein in a sample.
  • the present invention is particularly useful in fields such as chemistry, life science, analytical chemistry, and clinical testing.
  • a method for measuring a small amount of test substance contained in a sample using a reaction between substances having specific affinity such as antigen and antibody, sugar and lectin, nucleotide chain and complementary nucleotide chain, and ligand and receptor are known.
  • immunological measurement methods using an antigen-antibody reaction (immune reaction) between an antigen and an antibody are widely practiced.
  • CRP C-reactive protein
  • CRP is a protein that exhibits a precipitation reaction with C polysaccharides of pneumococcal bacteria, and an increase in blood CRP concentration may cause infections. It is evidence that the patient is afflicted or that inflammation is occurring in the body.
  • CRP has been used as a marker for various inflammations in order to diagnose diseases such as infections or inflammation.
  • a method for observing a specific reaction with C polysaccharide, and an antibody that binds to CRP (anti-CRP antibody) as a reagent, an antigen between CRP in the sample and anti-CRP antibody in the reagent examples thereof include a method for producing an antigen-antibody complex by an antibody reaction.
  • methods such as an immunonephelometric method, an immunoturbidimetric method, a latex immunoturbidimetric method, and the like, which are methods for generating an antigen-antibody complex with an anti-CRP antibody, are widely used in daily examinations.
  • this CRP is called a calcium binding protein and has a binding site with calcium ions in its three-dimensional structure, and CRP (calcium-binding CRP) bound to calcium ions has its three-dimensional structure (antigenicity).
  • CRP calcium-binding CRP
  • CRP binds to calcium ions in the blood of the animal to form calcium-binding CRP, and the animal inoculated with CRP has calcium-binding CRP.
  • the produced antibody includes “an antibody that binds to calcium-binding CRP but has a significantly reduced binding activity to calcium-unbinding CRP” and “calcium-binding CRP and calcium-unbinding CRP”. It is known that there are two types of antibodies, “antibodies that bind equally to each other” (see, for example, Non-Patent Document 1). "Clinical Pathology", Vol. 32, No. 2, pp. 223-224, published in 1984
  • the CRP concentration in the serum (or plasma) of healthy people is generally 0.3 mg / dL or less, but it rises by a sensitive reaction in a short time to inflammation and bacterial infection, and is 2,000 to 4,000 times Also reach. Since CRP concentration correlates with the magnitude and extent of inflammation or its improvement, the clinical significance of the measurement is great. Further, even if the CRP concentration is in the normal range (0.3 mg / dL or less), it is reported that the possibility of developing coronary artery disease is high when the concentration is relatively high, and has attracted attention. For this reason, in measuring CRP in a sample, it has been required to accurately measure CRP in a wide range of concentrations from low concentration to high concentration.
  • an object of the present invention is to measure CRP in a sample by measuring a complex aggregate produced by a specific binding reaction between CRP and a specific binding substance that binds to CRP immobilized on a carrier.
  • a measuring method and a measuring reagent that can expand the measuring range from a low concentration to a high concentration and accurately measure a wide range of CRP from a low concentration to a high concentration. That is.
  • a carrier on which a specific binding substance that binds to CRP is immobilized in a calcium ion-dependent manner is used to measure CRP in the sample.
  • the present invention provides the following inventions.
  • a specific binding substance that binds to a C-reactive protein in a calcium ion-dependent manner and a specific binding substance that binds to a C-reactive protein in a calcium ion-independent manner are immobilized on a carrier, respectively, By measuring a complex aggregate of the specific binding substance and the C-reactive protein produced by the specific binding reaction between the specific binding substance and the C-reactive protein contained in the sample.
  • a method for measuring C-reactive protein is a method for measuring C-reactive protein.
  • the C-reactive protein in the sample according to (1), wherein the specific binding substance that binds to the C-reactive protein in a calcium ion-dependent manner is an antibody that binds to the C-reactive protein in a calcium-ion-dependent manner How to measure.
  • the specific binding substance that binds to C-reactive protein independent of calcium ions is an antibody that binds to C-reactive protein independent of calcium ions.
  • the C-reactive protein in the sample according to (7), wherein the specific binding substance that binds to the C-reactive protein in a calcium ion-dependent manner is an antibody that binds to the C-reactive protein in a calcium-ion-dependent manner Measuring reagent.
  • the reagent for measuring C-reactive protein in the sample according to (7) or (8), wherein the antibody that binds to C-reactive protein in a calcium ion-dependent manner is a monoclonal antibody.
  • Any of the above (7) to (9), wherein the specific binding substance that binds to C-reactive protein independent of calcium ions is an antibody that binds to C-reactive protein independent of calcium ions.
  • a reagent for measuring C-reactive protein in a sample according to item 1. The reagent for measuring C-reactive protein in a sample according to any one of (7) to (10), wherein the antibody that binds to C-reactive protein independent of calcium ions is a monoclonal antibody.
  • a method for measuring CRP in a sample by measuring a complex aggregate produced by a specific binding reaction between CRP and a specific binding substance that binds to CRP immobilized on a carrier. And a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner in combination in the measurement reagent,
  • the measurement range can be expanded from a low concentration to a high concentration, and CRP in a wide range from a low concentration to a high concentration can be accurately measured.
  • FIG. 1 shows the binding of anti-CRP antibodies to calcium-bound CRP and calcium-unbound CRP.
  • FIG. 2 is a diagram showing the binding of anti-CRP antibodies to calcium-bound CRP and calcium-unbound CRP.
  • FIG. 3 is a diagram showing the binding of anti-CRP antibodies to calcium-bound CRP and calcium-unbound CRP.
  • FIG. 4 shows the binding of anti-CRP antibodies to calcium-bound CRP and calcium-unbound CRP.
  • FIG. 5 is a graph showing the difference in absorbance obtained by measuring CRP in a sample using a measurement reagent containing latex particles to which each anti-CRP antibody is immobilized.
  • FIG. 6 shows latex particles immobilized with an antibody (antibody-1) that binds to CRP in a calcium ion-dependent manner, and latex particles immobilized with an antibody (antibody-4) that binds to CRP in a calcium ion-independent manner. It is the figure which showed the light absorbency difference obtained by measuring CRP in a sample using the containing measurement reagent.
  • FIG. 7 shows latex particles immobilized with an antibody (antibody-2) that binds to CRP in a calcium ion-dependent manner, and latex particles immobilized with an antibody (antibody-4) that binds to CRP in a calcium ion-independent manner.
  • FIG. 8 shows latex particles in which an antibody that binds to CRP in a calcium ion-dependent manner (antibody-3) is immobilized, and latex particles in which an antibody that binds to CRP in a calcium ion-independent manner (antibody-4) is immobilized. It is the figure which showed the light absorbency difference obtained by measuring CRP in a sample using the containing measurement reagent.
  • FIG. 9 is a diagram showing the binding of anti-CRP antibodies to calcium-bound CRP and calcium-unbound CRP.
  • FIG. 10 is a graph showing the difference in absorbance obtained by measuring CRP in a sample using a measurement reagent containing latex particles on which an anti-CRP antibody is immobilized.
  • FIG. 11 shows latex particles immobilized with an antibody (antibody-1) that binds to CRP in a calcium ion-dependent manner and latex particles immobilized with an antibody (antibody-4) that binds to CRP in a calcium ion-independent manner. It is the figure which showed the light absorbency difference obtained by measuring CRP in a sample using the containing measurement reagent.
  • FIG. 12 shows latex particles immobilized with an antibody (antibody-2) that binds to CRP in a calcium ion-dependent manner, and latex particles immobilized with an antibody (antibody-4) that binds to CRP in a calcium ion-independent manner. It is the figure which showed the light absorbency difference obtained by measuring CRP in a sample using the containing measurement reagent.
  • FIG. 13 shows latex particles immobilized with an antibody (antibody-3) that binds to CRP in a calcium ion-dependent manner, and latex particles immobilized with an antibody (antibody-4) that binds to CRP in a calcium ion-independent manner.
  • FIG. 14 shows latex particles immobilized with an antibody (antibody-1) that binds to CRP in a calcium ion-dependent manner and latex particles immobilized with an antibody (antibody-5) that binds to CRP in a calcium ion-independent manner. It is the figure which showed the light absorbency difference obtained by measuring CRP in a sample using the containing measurement reagent.
  • FIG. 15 shows latex particles immobilized with an antibody (antibody-2) that binds to CRP in a calcium ion-dependent manner, and latex particles immobilized with an antibody (antibody-5) that binds to CRP in a calcium ion-independent manner. It is the figure which showed the light absorbency difference obtained by measuring CRP in a sample using the containing measurement reagent.
  • FIG. 16 shows latex particles immobilized with an antibody (antibody-3) that binds to CRP in a calcium ion-dependent manner, and latex particles immobilized with an antibody (antibody-5) that binds to CRP in a calcium ion-independent manner. It is the figure which showed the light absorbency difference obtained by measuring CRP in a sample using the containing measurement reagent.
  • the specific binding substance that binds to the C-reactive protein is a substance that can specifically bind to CRP, and is particularly limited as long as it is a substance that can specifically bind to CRP. There is no.
  • the specific binding substance that binds to CRP include an antibody that can bind to CRP (anti-CRP antibody), an aptamer (nucleic acid aptamer or peptide aptamer), an affibody, or a receptor.
  • antibodies that can bind to CRP include, for example, monoclonal antibodies, polyclonal antibodies, antisera, and antibody fragments [Fab and F (ab ′)) that can bind to CRP. 2 Etc.], or single chain antibodies (scFv) and the like.
  • the specific binding substance that binds to CRP is preferably an antibody that can bind to CRP (anti-CRP antibody), and more preferably the antibody is a monoclonal antibody.
  • Ca-dependent CRP-specific binding substance binds to calcium-binding CRP.
  • Non-binding CRP refers to a specific binding substance whose binding activity is significantly reduced. For example, as described above, in the presence of calcium ions, CRP bound to calcium ions changes a part of its three-dimensional structure.
  • the calcium ion bound to CRP binds to this chelating agent, and the three-dimensional structure (antigenicity) of CRP changes. End up.
  • the binding activity of the specific binding substance that binds to CRP in a calcium ion-dependent manner is significantly lower than that of CRP (calcium non-binding CRP) whose steric structure has been changed by the presence of a chelating agent.
  • the specific binding substance that binds to CRP in a calcium ion-dependent manner is a part in which the three-dimensional structure is changed by binding of CRP to calcium ion (if the specific binding substance is an antibody, this changing part is It is presumed to be a specific binding substance that recognizes antigenic determinants.
  • the specific binding substance that binds to C-reactive protein in a calcium ion-dependent manner is not particularly limited as long as it is a substance that can specifically bind to CRP in a calcium ion-dependent manner.
  • Examples of the substance capable of specifically binding to CRP in a calcium ion-dependent manner include, for example, an antibody, aptamer (nucleic acid aptamer or peptide aptamer), affibody, or receptor capable of binding to CRP in a calcium ion-dependent manner.
  • Examples of antibodies that can bind to CRP in a calcium ion-dependent manner include, for example, monoclonal antibodies, polyclonal antibodies, antisera, and antibody fragments [Fab or F (ab ') 2 Etc.], or single chain antibodies (scFv) and the like.
  • the antibody capable of binding to CRP in a calcium ion-dependent manner is an antibody (chimeric antibody, human that has been changed to an amino acid sequence of an animal species different from the animal immunizing the immunogen (CRP) by genetic recombination technology or the like. Or a fully humanized antibody).
  • the specific binding substance that binds to CRP in a calcium ion-dependent manner is preferably an antibody that can bind to CRP in a calcium ion-dependent manner, and more preferably the antibody is a monoclonal antibody.
  • two or more kinds of specific binding substances that bind to CRP in a calcium ion-dependent manner may be used.
  • Specific binding substance that binds to C-reactive protein independent of calcium ion is either a calcium-binding CRP or a non-calcium-binding CRP.
  • Bound CRP refers to a specific binding substance that binds to approximately the same extent. That is, for example, as described above, in the presence of calcium ions, CRP bound to calcium ions changes a part of its three-dimensional structure.
  • the calcium ion bound to CRP binds to this chelating agent, and the three-dimensional structure (antigenicity) of CRP changes. End up.
  • the specific binding substance that binds to CRP in a calcium ion-independent manner is CRP in which the three-dimensional structure has been changed by the presence of a chelating agent (non-calcium-binding CRP) and CRP to which calcium ions are bound. (Calcium-binding CRP) can bind to almost the same extent.
  • a specific binding substance that binds to CRP in a calcium ion-independent manner is a part other than the part where the steric structure is changed by binding of CRP to calcium ion (if the specific binding substance is an antibody, this part is determined by antigen It is speculated that this is a specific binding substance that recognizes the group).
  • the specific binding substance that binds to CRP independently of calcium ions is not particularly limited as long as it is a substance that can specifically bind to CRP independent of calcium ions.
  • Examples of substances that can specifically bind to CRP independent of calcium ions include, for example, antibodies, aptamers (nucleic acid aptamers or peptide aptamers), affibodies that can bind to CRP independent of calcium ions, Or a receptor etc. can be mentioned.
  • Examples of antibodies that can bind to CRP independent of calcium ions include, for example, monoclonal antibodies, polyclonal antibodies, antisera, and antibody fragments [Fab or F that can bind to CRP independent of calcium ions. (Ab ') 2 Etc.], or single chain antibodies (scFv) and the like.
  • this antibody capable of binding to CRP independent of calcium ions is an antibody (chimeric antibody, which has been changed to an amino acid sequence of an animal species different from an animal immunizing an immunogen (CRP) by genetic recombination technology or the like. It may be a humanized antibody or a fully humanized antibody).
  • the specific binding substance that binds to CRP independent of calcium ions is preferably an antibody that can bind to CRP independent of calcium ions, and more preferably the antibody is a monoclonal antibody.
  • two or more kinds of specific binding substances that bind to CRP independently of calcium ions may be used. And the specific binding substance couple
  • a method for preparing a polyclonal antibody that binds to CRP in a calcium ion-dependent manner or a polyclonal antibody that binds to CRP in a calcium ion-independent manner can be prepared by the following procedure.
  • an immunogen for antibody production all or part of CRP such as natural CRP, CRP obtained by genetic recombination, or a CRP-derived peptide can be used.
  • the above-mentioned immunogen, or the conjugate of the above-mentioned immunogen and carrier is used for mammals (mouse, nude mouse, rabbit, rat, sheep, goat, cow, horse, camel, etc.) or birds (chicken, ostrich, etc.) Immunize.
  • the amount of immunization of the immunogen or the conjugate of the immunogen and the carrier is determined by the type of immunized animal, the site of immunization, etc.
  • Each mouse is injected with 0.1 ⁇ g to 5 mg, preferably 50 ⁇ g to 2 mg of the immunogen or a conjugate of the immunogen and a carrier.
  • the immunogen or the combined immunogen and carrier is preferably added and mixed with an adjuvant for immunization injection.
  • an adjuvant known ones such as Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum hydroxide adjuvant or pertussis adjuvant can be used.
  • Immunization may be performed at a site such as subcutaneous, intravenous, intraperitoneal or back. After the initial immunization, booster injections of the immunogen or a conjugate of the immunogen and the carrier are given at sites such as subcutaneous, intravenous, intraperitoneal or back at intervals of 2 to 3 weeks.
  • the immunogen or the conjugate of the immunogen and the carrier is preferably boosted by adding an adjuvant and mixing.
  • the antibody titer in the serum of the immunized animal is repeatedly measured by ELISA or the like. When the antibody titer reaches a plateau, whole blood is collected, and the serum is separated to obtain an antiserum containing the antibody.
  • the antiserum is subjected to antibody purification by a salting-out method using ammonium sulfate, sodium sulfate or the like, ion exchange chromatography, gel filtration method or affinity chromatography, or a combination of these methods to obtain a polyclonal antibody.
  • the polyclonal antibody obtained here includes both a polyclonal antibody that binds to CRP in a calcium ion-dependent manner and a polyclonal antibody that binds to CRP in a calcium ion-independent manner. Is passed through an affinity chromatography column immobilized as a ligand on a solid phase in the presence of a chelating agent. Polyclonal antibodies that bind to CRP in a calcium ion-independent manner bind to the solid phase via the ligand (non-calcium-bound CRP) of this column and are collected.
  • a polyclonal antibody that binds to CRP in a calcium ion-dependent manner passes through this column without binding to the ligand (non-calcium-binding CRP) of this column.
  • a polyclonal antibody that binds to CRP in a calcium ion-dependent manner can be obtained.
  • a polyclonal antibody that binds to the CRP in a calcium ion-independent manner bound to a ligand (non-calcium-bound CRP) of this column is treated with a low pH solution.
  • a polyclonal antibody that binds to CRP in a calcium ion-independent manner can be obtained by releasing it from the ligand by a conventional method such as passing a solution containing a salt through a column and obtaining this fraction.
  • a conventional method such as passing a solution containing a salt through a column and obtaining this fraction.
  • antibodies against this carrier are present in the obtained polyclonal antibody. Therefore, removal of the antibody against such a carrier should be performed. Is preferred.
  • a carrier is added to the obtained polyclonal antibody solution to remove aggregates generated, or the carrier is immobilized on an insolubilized solid phase and removed by affinity chromatography. Can do.
  • a monoclonal antibody that binds to CRP in a calcium ion-dependent manner or a monoclonal antibody that binds to CRP in a calcium ion-independent manner can be prepared by the following procedure.
  • Monoclonal antibodies can be produced using a hybridoma produced by Keller et al.'S cell fusion method (G. Koehler et al., Nature, 256, 495-497, published in 1975) using Epstein-Barr virus (EB virus) that causes lymphoma.
  • EB virus Epstein-Barr virus
  • a method for increasing lymphocytes a method for genetically manipulating microorganisms such as cultured cells derived from mouse bone marrow or yeast.
  • Preparation of a monoclonal antibody by the cell fusion method can be performed by the following operation.
  • an immunogen for antibody production all or part of CRP such as natural CRP, CRP obtained by genetic recombination, or a CRP-derived peptide can be used.
  • the immunogen, or the conjugate of the immunogen and the carrier is used in a mammal (mouse, nude mouse, rabbit, rat, sheep, goat, cow, horse, camel, etc., for example, BALB / c of an inbred mouse.
  • the immunization amount of the immunogen or the conjugate of the immunogen and the carrier can be appropriately determined depending on the type of immunized animal, the site of immunization, and the like. Preferably, 0.1 ⁇ g to 5 mg, preferably 50 ⁇ g to 2 mg of the immunogen or a combination of the immunogen and a carrier is immunized at a time.
  • the immunogen or the conjugate of the immunogen and the carrier is preferably immunized by adding an adjuvant and mixing.
  • Known adjuvants such as Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum hydroxide adjuvant, or pertussis adjuvant can be used as the adjuvant.
  • Immunization may be performed at a site such as subcutaneous, intravenous, intraperitoneal or back.
  • booster injections of the immunogen or a conjugate of the immunogen and the carrier are given at sites of subcutaneous, intravenous, intraperitoneal, or back at 1-2 week intervals.
  • the number of booster injections is generally 2 to 6 times.
  • the immunogen or the combined immunogen and carrier is preferably boosted by adding an adjuvant and mixing.
  • the antibody titer in the serum of the immunized animal is repeatedly measured by ELISA (enzyme immunoassay) or the like.
  • the immunogen or the immunogen and the carrier A solution obtained by dissolving the conjugate in physiological saline (0.9% sodium chloride aqueous solution) is injected intravenously or intraperitoneally to obtain the final immunization.
  • physiological saline 0.9% sodium chloride aqueous solution
  • cells having antibody-producing ability such as spleen cells, lymph node cells or peripheral lymphocytes of immunized animals are obtained.
  • the cell having antibody-producing ability obtained from this immunized animal is fused with myeloma cells (myeloma cells) of mammals (mouse, nude mouse, rat, etc.).
  • a cell line deficient in an enzyme such as guanine phosphoribosyl transferase (HGPRT) or thymidine kinase (TK) is preferred.
  • HGPRT guanine phosphoribosyl transferase
  • TK thymidine kinase
  • the P3-X63-Ag8 strain ATCC which is a HGPRT-deficient cell line derived from BALB / c mice. TIB9), P3-X63-Ag8-U1 strain (Cancer Research Source Bank (JCRB) 9085), P3-NS1-1-Ag4-1 strain (JCRB 0009), P3-X63-Ag8.653 strain (JCRB 0028)
  • SP2 / O-Ag-14 strain (JCRB 0029) or the like is used. be able to.
  • Cell fusion can be performed using a fusion promoter such as polyethylene glycol (PEG) of various molecular weights, liposomes or Sendai virus (HVJ), or by electrofusion.
  • a fusion promoter such as polyethylene glycol (PEG) of various molecular weights, liposomes or Sendai virus (HVJ)
  • PEG polyethylene glycol
  • HVJ Sendai virus
  • fusion of cells having antibody-producing ability and myeloma cells by using a selection medium (HAT medium) containing hypoxanthine, aminopterin, and thymidine Only cells (hybridomas) can be selectively cultured and propagated.
  • the hybridoma culture supernatant thus obtained was measured for its binding to calcium-bound CRP and calcium-unbound CRP by ELISA as described later, and a monoclonal antibody produced from the hybridoma was obtained.
  • Production of a monoclonal antibody that binds to CRP in a calcium ion-dependent manner by determining whether it is a monoclonal antibody that binds to CRP in a calcium ion-dependent manner or a monoclonal antibody that binds to CRP in a calcium ion-independent manner.
  • a hybridoma producing a monoclonal antibody that binds to CRP in a calcium ion-independent manner is determining whether it is a monoclonal antibody that binds to CRP in a calcium ion-dependent manner or a monoclonal antibody that binds to CRP in a calcium ion-independent manner.
  • a monoclonal antibody-producing cell line that binds to CRP in a calcium ion-dependent manner or a monoclonal antibody that binds to CRP in a calcium ion-independent manner Each antibody-producing cell line can be isolated and obtained.
  • a monoclonal antibody that binds to CRP in a calcium ion-dependent manner or a monoclonal antibody that binds to CRP in a calcium ion-independent manner can be obtained from the culture supernatant.
  • a serum-free medium or a low-concentration serum medium may be used as the medium.
  • a medium such as DMEM medium, RPMI 1640 medium, or ASF medium 103 is preferably used because the antibody can be easily purified. it can.
  • a monoclonal antibody-producing cell line can be injected into the abdominal cavity of a mammal that is compatible with this and previously stimulated with pristane or the like, and the monoclonal antibody can be obtained from ascites collected in the abdominal cavity after a certain period of time. .
  • the monoclonal antibody thus obtained was purified by a salting-out method using ammonium sulfate, sodium sulfate or the like, a method such as ion exchange chromatography, gel filtration or affinity chromatography, or a combination of these methods. It can be obtained as a monoclonal antibody.
  • a “specific binding substance that binds to CRP” that binds to approximately the same degree in both calcium-bound CRP and non-calcium-bound CRP is a specific binding substance that binds to CRP independent of calcium ions.
  • (B) Preparation of reagents A) Preparation of CRP-immobilized microplate CRP is brought into contact with each well of a 96-well microtiter plate, adsorbed and immobilized to prepare a CRP-immobilized microplate.
  • (B) Preparation of enzyme-labeled antibody An “enzyme-labeled antibody” is prepared by labeling an enzyme with an antibody that can specifically bind to a “specific binding substance that binds to CRP” to be determined. [For example, when the specific binding substance that binds to CRP is an anti-CRP mouse antibody, an enzyme-labeled anti-mouse IgG antibody or the like can be used as this enzyme-labeled antibody.
  • C Preparation of cleaning solution
  • a surfactant is dissolved in pure water to prepare a cleaning solution.
  • D Preparation of color developing solution
  • a color developing solution containing a substance related to a reaction that causes color development is prepared.
  • B Sample
  • a calcium salt is dissolved in pure water to prepare a calcium ion-containing aqueous solution.
  • a chelating agent is dissolved in pure water to prepare a chelating agent-containing aqueous solution.
  • the CRP immobilized in this well becomes a calcium-binding CRP bonded to calcium ions. Then, it is allowed to stand for a certain period of time, and a specific binding reaction between the specific binding substance that binds to CRP contained in the sample and the calcium binding type CRP immobilized in the well is performed.
  • the “sample of a specific binding substance that binds to a chelating agent-containing CRP” in (d) of (b) above is placed in the other well of the CRP-immobilized microplate of (a) in (a). Added. As a result, the CRP immobilized in this well becomes a calcium non-binding CRP.
  • the enzyme-labeled antibody is bound to the “specific binding substance that binds to CRP” bound to the well of the CRP-immobilized microplate via calcium-bound CRP or calcium-unbound CRP.
  • E After sucking and removing the liquid in each well, the washing liquid is added to each well, and this is sucked and removed to perform washing. This washing operation is repeated several times.
  • F Next, the color developing solution (d) of (b) is added to each well and allowed to stand for a certain period of time.
  • the “enzyme-labeled antibody” labeled enzyme bound to the well of the CRP-immobilized microplate via “specific binding substance that binds to CRP” and “calcium-bound CRP or calcium-unbound CRP” Then, a color development reaction is performed by a reaction with a substance contained in the color development solution.
  • G The absorbance of the liquid in each well is measured using a microplate reader or the like at a wavelength suitable for measuring the color development.
  • H Except that the negative sample is used in place of the sample, the procedure is performed as in (a) to (g), and the absorbance is measured.
  • the absorbance difference value calculated by subtracting the absorbance measured in (h) from the absorbance measured in (g) in the well in which calcium-binding CRP is immobilized is obtained.
  • the absorbance difference value reflects the binding property of the “specific binding substance that binds to CRP” with “calcium-binding CRP”.
  • the value of the absorbance difference calculated by subtracting the absorbance measured in (h) from the absorbance measured in (g) in the well in which the calcium non-binding CRP is immobilized is obtained.
  • the value of the absorbance difference is a value reflecting the binding of the “specific binding substance that binds to CRP” with “calcium non-binding CRP”, and the higher this absorbance difference value, It shows that the “specific binding substance that binds to CRP” has high binding property to “calcium non-binding CRP”. The lower the absorbance difference value, the lower the binding property of “specific binding substance that binds to CRP” with “calcium non-binding CRP”.
  • the value of the difference in absorbance obtained by measurement according to the description of ” is plotted on the vertical axis, and the concentration of“ specific binding substance that binds to CRP ”of the measured sample is plotted on the horizontal axis, and calcium-binding CRP is immobilized.
  • a graph (figure) in which the measured value (absorbance difference) in the well and the measured value (absorbance difference) in the well in which the calcium non-binding CRP is immobilized is plotted is prepared.
  • the “specific binding substance that binds to CRP” in the sample is determined to be “specific binding substance that binds to CRP independent of calcium ions”.
  • the specific binding substance that binds to CRP is “a specific binding substance that binds to CRP in a calcium ion-dependent manner” or “independent of calcium ions” as follows. It is possible to determine whether or not it is a “specific binding substance that binds to CRP”.
  • the “difference in absorbance” is the value of “A / 2” in (c) above.
  • the value (C2) of the concentration of “specific binding substance” is determined.
  • the value of “C1” is compared with the value of “C2” to obtain the value of “C2 / C1”.
  • the “specific binding substance that binds to CRP” in the sample is “specific binding substance that binds to CRP in a calcium ion-dependent manner”.
  • the “specific binding substance that binds to CRP” in the sample is expressed as “calcium ion dependent CRP. It is determined that it is a “specific binding substance that binds”.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized In the present invention, the specific binding substance that binds to CRP in a calcium ion-dependent manner and the carrier on which the specific binding substance that binds to CRP in a calcium ion-independent manner is bound to CRP in the calcium ion-dependent manner. And a specific binding substance that binds to CRP independent of calcium ions is immobilized on a carrier.
  • the specific binding substance that binds to CRP in a calcium ion-dependent manner and the carrier on which the specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized has a specific binding that binds to CRP in a calcium ion-dependent manner. It may be a mixture of a carrier on which a substance is immobilized and a carrier on which a specific binding substance that binds to CRP independent of calcium ions is immobilized.
  • the mixing ratio of the carrier immobilizing a specific binding substance that binds to CRP in a calcium ion-dependent manner and the carrier immobilizing a specific binding substance that binds to CRP in a calcium ion-independent manner depends on the mixing ratio used.
  • the specific binding substance and the type of carrier to be used vary depending on the conditions and the like, and thus cannot be generally stated. For example, it is possible to use a mixture in which both carriers have the same concentration.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized has a specific binding that binds to CRP in a calcium ion-dependent manner.
  • the substance and a specific binding substance that binds to CRP independent of calcium ions may be immobilized on the same carrier.
  • the ratio between the specific binding substance that binds to CRP in a calcium ion-dependent manner and the specific binding substance that binds to CRP in a calcium ion-independent manner depends on the specific binding substance used and the type of carrier used.
  • both specific binding substances are immobilized on a carrier so as to have the same ratio.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized has a specific specificity that binds to CRP in a calcium ion-dependent manner.
  • a carrier having a binding substance immobilized thereon a carrier having a specific binding substance which binds to CRP independent of calcium ions, a specific binding substance which binds to CRP in a calcium ion dependent manner, and calcium
  • the specific binding substance that binds to CRP in an ion-independent manner may be a mixture of those immobilized on the same carrier.
  • the material of this carrier is not particularly limited. For example, polystyrene, styrene-styrene sulfonate copolymer, acrylonitrile-butadiene-styrene copolymer, vinyl chloride-acrylic acid ester copolymer, vinyl acetate-acrylic acid copolymer.
  • the carrier may be particles such as latex particles, liposomes, microcapsules, or red blood cells.
  • the carrier in the present invention is preferably particles, and particularly preferably latex particles.
  • Immobilization of a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner is carried out by physical adsorption, chemical binding, or these It can carry out by well-known methods, such as combined use.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and / or a specific binding substance that binds to CRP in a calcium ion-independent manner and a carrier are buffered.
  • the chemical binding method the “Clinical Pathology Special Issue 53: Immunoassay for Clinical Examinations—Technology and Applications” edited by the Japanese Society of Clinical Pathology, Clinical Pathology Publications, 1983; Japan Biochemical Society In accordance with a known method described in ed. “Shinsei Kagaku Kenkyu Ken 1 Protein IV”, published by Tokyo Kagaku Dojin, published in 1991, etc.
  • a bivalent cross-linking reagent such as glutaraldehyde, carbodiimide, imide ester, or maleimide
  • Hexyl group, a thiol group can be carried out such as by reacting a bifunctional crosslinking reagent of the aldehyde group or a hydroxyl group.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner, and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is bound binds to CRP in a calcium ion-dependent manner.
  • a carrier immobilizing a substance and a carrier immobilizing a specific binding substance that binds to CRP in a calcium ion-independent manner it binds to CRP in a calcium ion-dependent manner by the method described above.
  • Examples thereof include a method in which a specific binding substance is immobilized on a carrier, a specific binding substance that binds to CRP independent of calcium ions is immobilized on the carrier, and these two kinds of carriers are mixed.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized binds to CRP in a calcium ion-dependent manner.
  • the specific binding substance that binds to CRP dependently of calcium ions and A specific binding substance that binds to CRP in a calcium ion-dependent manner by preparing a solution containing both of the specific binding substances that bind to CRP in a calcium ion-independent manner and bringing the solution into contact with a carrier by the above-described method or the like And a method of immobilizing a specific binding substance that binds to CRP in a calcium ion-independent manner on the same carrier.
  • the bovine serum albumin is immobilized on the surface of a carrier on which a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized.
  • the size (particle size) of a carrier such as latex particles is not particularly limited.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized is a complex with CRP contained in the sample.
  • the size (particle diameter) of the carrier is 0 (average particle diameter).
  • the thickness is preferably 0.01 ⁇ m to 10 ⁇ m, more preferably 0.04 ⁇ m to 1 ⁇ m.
  • two or more types of carriers different in size (particle size), material, shape, etc. may be used as the carrier.
  • a turbidimetric method such as latex turbidimetric method
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a CRP independent of calcium ions.
  • the concentration of the carrier on which the specific binding substance that binds to the carrier is immobilized during the measurement reaction is the distribution density of the specific binding substance on the carrier surface, the size of the carrier (particle size), and the mixture of the sample and the measurement reagent. Since the optimum concentration differs depending on various conditions such as the ratio, it cannot be generally stated.
  • a sample and a measurement reagent are mixed, a specific binding substance that binds to CRP in a calcium ion-dependent manner immobilized on a carrier, and a specific binding substance that binds to CRP in a calcium ion-independent manner;
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner during a measurement reaction in which a specific binding reaction with CRP contained in the sample is performed In general, the concentration of the carrier on which the carrier is immobilized is 0.005 to 1% (w / v) in the reaction mixture during the measurement reaction.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner are fixed. It is preferable to include a standardized carrier in the measurement reagent.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized is used as bovine serum albumin (BSA), proteins such as human serum albumin (HSA), casein or salts thereof; various metal ions such as calcium ions; various salts such as calcium salts; various saccharides; skim milk powder; various animal sera such as normal rabbit serum; Various preservatives such as sodium phosphide or antibiotics; activating substances; reaction promoting substances; sensitivity increasing substances such as polyethylene glycol; nonspecific reaction inhibiting substances; or nonionic surfactants, amphoteric surfactants or anions You may make it coexist with 1 type, or 2 or more types, such as various surfactants, such as an ionic surfactant.
  • BSA bovine serum albumin
  • HSA human serum albumin
  • casein casein
  • various metal ions such as calcium ions
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized It is preferable to coexist with ions or calcium salts.
  • the concentration when the above substances coexist is not particularly limited, but is preferably 0.001 to 10% (W / V), and particularly preferably 0.01 to 5% (W / V). .
  • sample refers to a sample in which CRP may be present and the presence or absence or content (concentration) of CRP is to be measured.
  • sample examples include body fluids such as human or animal blood, serum, plasma, spinal fluid or ascites, or extracts such as organs, tissues or cells, which may contain CRP. be able to.
  • Container The container used for the method for measuring CRP in the sample of the present invention is not particularly limited, and a suitable one can be used.
  • Measuring reagent The reagent for measuring CRP in a sample according to the present invention contains a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized. It is characterized by.
  • the measurement reagent of the present invention may consist of one measurement reagent.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized is contained in one of the measurement reagents.
  • the measurement reagent of the present invention may be composed of two or more measurement reagents.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized is one of two or more measurement reagents. It may be contained in a measurement reagent, or may be contained in two or more measurement reagents.
  • the measurement reagent of the present invention is composed of two measurement reagents, a first reagent and a second reagent, a specific binding substance that binds to CRP in a calcium ion-dependent manner, and calcium ion-independent
  • the carrier on which the specific binding substance that binds to CRP is immobilized may be contained only in the first reagent, may be contained only in the second reagent, and further, the first reagent and the second reagent. You may make it contain in both.
  • the measurement reagent of the present invention comprises two measurement reagents, a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized Is preferably contained only in the second reagent.
  • the measurement reagent of the present invention is composed of two or more measurement reagents, a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner.
  • a reagent other than a reagent containing a carrier on which a binding substance is immobilized that is, a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner are immobilized.
  • the reagent not containing a carrier may be, for example, a buffer solution.
  • various aqueous solvents can be used as a solvent for the measurement reagent of the present invention. Examples of the aqueous solvent include purified water, physiological saline, or various buffer solutions such as tris (hydroxymethyl) aminomethane buffer, phosphate buffer, or phosphate buffered saline. .
  • the pH of the buffer solution may be appropriately selected and used as appropriate. Although there is no particular limitation, it is general to select and use a pH within the range of pH 5 to pH 10. Further, the specific binding substance that binds to CRP in a calcium ion-dependent manner and the specific binding substance that binds to CRP in a calcium ion-independent manner are immobilized on the CRP measurement reagent in the sample of the present invention.
  • proteins such as bovine serum albumin (BSA), human serum albumin (HSA), casein or salts thereof; various metal ions such as calcium ions; various salts such as calcium salts; various sugars; skim milk powder; normal rabbits
  • various animal sera such as serum; various preservatives such as sodium azide or antibiotics; activating substances; reaction promoting substances; sensitivity increasing substances such as polyethylene glycol; nonspecific reaction inhibiting substances; or nonionic surfactants
  • One or more of various surfactants such as amphoteric surfactant or anionic surfactant It may be contained as appropriate.
  • the measurement reagent of the present invention preferably contains calcium ions or calcium salts.
  • the concentration when these are contained in the measurement reagent of the present invention is not particularly limited, but is preferably 0.001 to 10% (W / V), particularly 0.01 to 5% (W / V). ) Is preferred.
  • the surfactant include sorbitan fatty acid ester, glycerin fatty acid ester, decaglycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene alkyl ether, Nonionic surfactants such as polyoxyethylene phytosterol, phytostanol, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkylphenyl ether, polyoxyethylene castor oil, hydrogenated castor oil or polyoxyethylene lanolin; betaine acetate, etc.
  • the reagent for measuring CRP in the sample of the present invention can be sold alone or used for measuring CRP in the sample.
  • the CRP measuring reagent in the sample of the present invention can be sold in combination with other reagents or used for measuring CRP in the sample.
  • the other reagent include a buffer solution, a sample diluent, a reagent diluent, a reagent containing a labeling substance, a reagent containing a substance that generates a signal such as color development, or calibration (calibration).
  • Measuring method In the method for measuring CRP in a sample according to the present invention, a specific binding substance that binds to CRP in a calcium ion-dependent manner and a specific binding substance that binds to CRP in a calcium ion-independent manner are immobilized on a carrier, respectively.
  • CRP in the sample is measured by measuring a complex aggregate of the specific binding substance and CRP generated by the specific binding reaction between the specific binding substance immobilized on the CRP and the CRP contained in the sample. Is a method of measuring.
  • the measurement operation in the method for measuring CRP in the sample of the present invention can be performed according to a known measurement operation.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner and a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized for example, “binding to CRP in a calcium ion-dependent manner” A mixture of a carrier having a specific binding substance immobilized thereon and a carrier having a specific binding substance immobilized on CRP in a calcium ion-independent manner, or “specific binding binding to CRP in a calcium ion-dependent manner”
  • a measurement reagent containing a substance and a specific binding substance that binds to CRP in a calcium ion-independent manner immobilized on the same carrier is prepared and prepared.
  • the sample is mixed with a specific binding substance that binds to CRP in a calcium ion-dependent manner and a measurement reagent containing a carrier on which a specific binding substance that binds to CRP in a calcium ion-independent manner is immobilized, Make contact.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner immobilized on a carrier, a specific binding substance that binds to CRP in a calcium ion-independent manner, and the CRP contained in the sample A specific binding reaction is performed.
  • a specific binding substance that binds to CRP in a calcium ion-dependent manner immobilized on the carrier, and a specific binding substance that binds to CRP in a calcium ion-independent manner, which are generated by this specific binding reaction Measure complex aggregates.
  • the measurement of the generated complex aggregate should be performed by measuring the absorbance of the reaction mixture, such as transmitted light or scattered light, in the measurement reaction in which the complex aggregate is present by the endpoint method or the rate method. To implement. Then, the measured value such as the absorbance obtained by measuring the sample is compared with the measured value such as the absorbance obtained by measuring the standard substance (sample having a known CRP concentration), and the CRP contained in the sample is measured. The concentration (quantitative value) of is calculated.
  • the measurement of absorbance such as transmitted light or scattered light may be performed by measuring transmitted light or scattered light, and may be one-wavelength measurement or two-wavelength measurement (two It may be a difference or ratio depending on the wavelength.
  • the measurement wavelength is generally selected from 340 nm to 1,000 nm.
  • the measurement of CRP in the sample of the present invention may be performed by a method, or may be performed using an apparatus such as a measuring apparatus.
  • the measuring device may be a general-purpose automatic analyzer or a dedicated measuring device (dedicated machine).
  • this measurement may be performed by a one-step method (one-reagent method) or by a method performed by a plurality of operation steps such as a two-step method (two-reagent method).
  • First reagent Buffer solution containing a buffer and adjusting the pH to a constant value
  • Second reagent Buffer containing an antibody that binds to CRP in a calcium ion-dependent manner and an antibody that binds to CRP in a calcium ion-independent manner immobilized on the same latex particle
  • the temperature at the time of standing is preferably a constant temperature within a range of room temperature (1 ° C. to 30 ° C.) or slightly warm (30 ° C. to 40 ° C.).
  • the standing time is preferably a fixed time of 1 minute or more and 10 minutes or less, and more preferably a fixed time of 3 minutes or more and 5 minutes or less.
  • An antibody that binds to CRP in a calcium ion-dependent manner immobilized on latex particles by adding a second reagent to the mixed solution of the sample and the first reagent, and an antibody that binds to CRP in a calcium ion-independent manner; Then, an antigen-antibody reaction (measurement reaction) with CRP contained in the sample is performed. Then, by this antigen-antibody reaction (measurement reaction), "...
  • the reaction mixture is irradiated with light, and a decrease in transmitted light intensity at an appropriate wavelength, which is a signal generated by a composite aggregate of latex particles generated (absorbance) ) Or an increase in scattered light intensity, the amount of the complex aggregate produced, that is, the amount of CRP contained in the sample is determined.
  • each of the four anti-CRP antibodies is an antibody that binds to CRP in a calcium ion-dependent manner by the sandwich method of ELISA (enzyme immunoassay), or It was determined whether the antibody binds to CRP in a calcium ion-independent manner.
  • CRP-immobilized plate The recombinant CRP (Oriental Yeast Co., Ltd.) was diluted with 10 mM phosphate buffered saline [pH 7.4 (20 ° C.)] to a concentration of 5 ⁇ g / mL, 50 ⁇ L per well was added to a 96-well microtiter plate (NUNK) and allowed to stand at 37 ° C. for 2 hours to adsorb and immobilize the CRP in each well of the microplate. The microtiter plate on which the CRP is immobilized is washed by adding 300 ⁇ L of the washing solution (2) per well, and this washing is performed 5 times in total, and then 0.5% containing 0.05% sodium azide.
  • NUNK 96-well microtiter plate
  • Preparation of Antibody Sample (1) Preparation of Diluent A Calcium chloride was dissolved in a 0.5% casein aqueous solution so as to have a concentration of 2 mM. (2) Preparation of Diluent B Prepared by dissolving EDTA.2 sodium salt (Dojindo Laboratories), which is a chelating agent, in a 0.5% casein aqueous solution so as to have a concentration of 10 mM. did. (3) Anti-CRP antibodies The following four types of commercially available antibodies were prepared as anti-CRP antibodies.
  • Antibody-1 Mouse anti-human CRP monoclonal antibody [clone: CRB-018] (Japan Biotest Laboratories)
  • Antibody-2 Mouse anti-human CRP monoclonal antibody [clone: CRB-023] (Japan Biotest Laboratories)
  • Antibody-3 Mouse anti-human CRP monoclonal antibody [clone: CRB-031] (Japan Biotest Laboratories)
  • Antibody-4 Mouse anti-human CRP monoclonal antibody [clone: CRB-032] (Japan Biotest Laboratories) (4) Preparation of antibody sample
  • (a) Calcium ion-containing anti-CRP antibody sample The four types of anti-CRP antibodies from antibody-1 to antibody-4 of (3) above were prepared in the diluent A prepared in (1) above.
  • Each antibody sample was prepared. Further, the diluent A prepared in the above (1) was used as a calcium ion-containing anti-CRP antibody sample having an anti-CRP antibody concentration of 0 ⁇ g / mL.
  • (B) EDTA-containing / anti-CRP antibody sample The four types of anti-CRP antibodies from antibody-1 to antibody-4 in (3) above were each diluted with the diluent B prepared in (2) above to obtain anti-CRP antibodies.
  • EDTA-containing / anti-CRP antibody samples having concentrations of 0.010 ⁇ g / mL, 0.10 ⁇ g / mL, 1.0 ⁇ g / mL, 10.0 ⁇ g / mL, or 100.0 ⁇ g / mL, respectively, were prepared. Further, the diluent B prepared in the above (2) was used as an EDTA-containing anti-CRP antibody sample having an anti-CRP antibody concentration of 0 ⁇ g / mL. 3.
  • the CRP immobilized in each well of the CRP-immobilized plate becomes calcium-binding CRP by adding and contacting the calcium ion-containing / anti-CRP antibody sample. Therefore, at this time, the binding property of each anti-CRP antibody to the calcium-binding CRP immobilized in each well is tested.
  • C Thereafter, the calcium ion-containing anti-CRP antibody sample in each well of the CRP-immobilized plate is removed by aspiration, and the washing solution prepared in (1) above is added to each well in an amount of 400 ⁇ L per well. This was washed a total of 5 times.
  • the anti-CRP antibody concentrations are 0.010 ⁇ g / mL, 0.10 ⁇ g / mL, 1.0 ⁇ g / mL, and 10.0 ⁇ g / mL for each of the four types of anti-CRP antibodies from antibody-1 to antibody-4.
  • the measurement value (absorbance) of the calcium ion-containing anti-CRP antibody sample with 100.0 ⁇ g / mL is subtracted from the measurement value (absorbance) of the calcium ion-containing anti-CRP antibody sample with an anti-CRP antibody concentration of 0 ⁇ g / mL. Then, the value of the absorbance difference was determined.
  • the calcium ions bound to the CRP immobilized in each well of the CRP-immobilized plate by the addition and contact of the EDTA-containing / anti-CRP antibody sample were:
  • the CRP immobilized in each of the wells by binding with EDTA ⁇ 2Na is a calcium non-binding CRP. Therefore, at this time, the binding property of each anti-CRP antibody to the calcium non-binding CRP immobilized in each well is tested.
  • the horizontal axis represents the concentration ( ⁇ g / mL) of the anti-CRP antibody in the antibody sample added to the well of the CRP-immobilized plate, and the vertical axis represents the measurement.
  • the obtained absorbance difference value (415 nm) is represented.
  • “ ⁇ ” indicates the measurement result (absorbance difference) when each calcium ion-containing / anti-CRP antibody sample is measured, and “ ⁇ ” indicates each The measurement results (absorbance difference) when an EDTA-containing anti-CRP antibody sample is measured are shown. 4). Discussion (a) From the above examination results, antibody-1 (FIG. 1), antibody-2 (FIG. 2), and antibody-3 (FIG.
  • the curve of the measurement results (calcium ion-containing anti-CRP antibody sample) showing the binding property of the anti-CRP antibody to the calcium-binding CRP and the calcium of the anti-CRP antibody
  • the curves of the measurement results (EDTA-containing anti-CRP antibody sample) showing the binding property to the non-binding CRP are hardly separated. That is, it can be seen that antibody-4 binds to approximately the same extent as both calcium-bound CRP and calcium-unbound CRP. From this, it can be determined that the antibody-4 is a “specific binding substance (antibody) that binds to CRP independent of calcium ions”.
  • Reagent (1) 1st reagent 100% tris (hydroxymethyl) aminomethane containing 1% (w / v) BSA, 2M sodium chloride, 0.2mM calcium chloride dihydrate and 0.05% sodium azide -A hydrochloric acid buffer (pH 8.0 (20 ° C)) was prepared and used as the first reagent.
  • Second reagent [antibody-1] Antibody (1) in Example 1, 2 (3) -1 [specific binding substance (antibody) that binds to CRP dependently on calcium ion) in 0.094 mL of a 10% suspension of latex particles having an average particle size of 0.1 ⁇ m ] In a concentration of 0.1 g / dL in 6.7 mM MES buffer [pH 5.0 (20 ° C.)] was added, and the mixture was stirred at 5 ° C. overnight. Thereby, the antibody-1 was immobilized on latex particles.
  • Second reagent [antibody-4] Except that the antibody-1 in (a) is changed to the antibody-4 [specific binding substance (antibody) that binds to CRP in a calcium ion-independent manner) in 2 (3) of Example 1, The operation was performed as described in (a) to prepare a 0.060% suspension of latex particles on which antibody-4 was immobilized. This was designated as a second reagent [antibody-4]. 2.
  • Sample (1) Preparation of Sample Diluent 50 mM Tris (hydroxymethyl) aminomethane-hydrochloric acid containing 4% (w / v) BSA, 0.2 mM calcium chloride dihydrate, 100 mM sodium chloride and 15 mM sodium azide A buffer solution [pH 7.6] was prepared and used as a sample diluent.
  • a buffer solution [pH 7.6] was prepared and used as a sample diluent.
  • Each sample of the following CRP concentration was prepared by diluting genetically modified CRP (manufactured by Oriental Yeast Co., Ltd.) with the sample diluent of (1) above. Further, physiological saline (0.9% sodium chloride aqueous solution) was used as a sample having a CRP concentration of 0 mg / dL.
  • the anti-CRP antibody of “carrier (latex particles) on which anti-CRP antibody is immobilized” to be contained in the CRP measurement reagent in the sample is expressed as “calcium ion dependent CRP.
  • CRP in the sample is in a low concentration range.
  • the reactivity with CRP is low and the sensitivity of the measurement is not high, but the reactivity with CRP is high from the medium concentration range to the high concentration range, and the value of the absorbance difference increases as the CRP concentration in the sample increases. It can be seen that the amount of complex aggregates increases as the CRP concentration in the sample increases.
  • the anti-CRP antibody of the “carrier (latex particle) on which the anti-CRP antibody is immobilized” to be contained in the CRP measurement reagent in the sample is “calcium ion-independent.
  • antibody-4 that is, when “specific binding substance (antibody) that binds to CRP independent of calcium ion” is used, it is highly sensitive in a low concentration range. In addition, it was confirmed that the measurement was not quantitative in the middle concentration range to the high concentration range.
  • the present invention comprising latex particles immobilized with an antibody (antibody-1) that binds to CRP in a calcium ion-dependent manner and latex particles immobilized with an antibody (antibody-4) that binds to a CRP in a calcium ion-independent manner.
  • the CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed. 1.
  • Reagent (1) 1st reagent 100% tris (hydroxymethyl) aminomethane containing 1% (w / v) BSA, 2M sodium chloride, 0.2mM calcium chloride dihydrate and 0.05% sodium azide -A hydrochloric acid buffer (pH 8.0 (20 ° C)) was prepared and used as the first reagent.
  • Second Reagent (a) Antibody-1 Immobilized Latex Particle Suspension To 0.094 mL of 10% suspension of latex particles having an average particle size of 0.1 ⁇ m, (2) of Example 1-2 Antibody-1 [specific binding substance (antibody) that binds to CRP in a calcium ion-dependent manner] mixed with 6.7 mM MES buffer (pH 5.0 (20 ° C.)) at a concentration of 0.1 g / dL 0.5098 mL was added and it stirred at 5 degreeC overnight.
  • MES buffer pH 5.0 (20 ° C.
  • Sample (1) Preparation of Sample Diluent 50 mM Tris (hydroxymethyl) aminomethane-hydrochloric acid containing 4% (w / v) BSA, 0.2 mM calcium chloride dihydrate, 100 mM sodium chloride and 15 mM sodium azide A buffer solution [pH 7.6] was prepared and used as a sample diluent.
  • a buffer solution [pH 7.6] was prepared and used as a sample diluent.
  • Each sample of the following CRP concentration was prepared by diluting genetically modified CRP (manufactured by Oriental Yeast Co., Ltd.) with the sample diluent of (1) above. Further, physiological saline (0.9% sodium chloride aqueous solution) was used as a sample having a CRP concentration of 0 mg / dL.
  • FIG. 6 show the absorbance difference obtained by measuring CRP in the sample in (1).
  • the horizontal axis represents the CRP concentration (mg / dL) in the sample
  • the vertical axis represents the absorbance difference value obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • the second reagent is “second reagent [antibody-4]”
  • the CRP in the sample is highly sensitive when it is in the low concentration range, but the medium concentration range to the high concentration range. It can be seen that the measurement does not have the quantitativeness of measurement.
  • the present invention comprising latex particles immobilized with an antibody (antibody-2) that binds to CRP in a calcium ion-dependent manner and latex particles immobilized with an antibody (antibody-4) that binds to a CRP in a calcium ion-independent manner.
  • the CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed.
  • Reagent (1) 1st reagent 100% tris (hydroxymethyl) aminomethane containing 1% (w / v) BSA, 2M sodium chloride, 0.2mM calcium chloride dihydrate and 0.05% sodium azide -A hydrochloric acid buffer (pH 8.0 (20 ° C)) was prepared and used as the first reagent.
  • Second Reagent (a) Antibody-2 Immobilized Latex Particle Suspension To 0.094 mL of a 10% suspension of latex particles having an average particle size of 0.1 ⁇ m, (2) of Example 1-2 Antibody-2 [specific binding substance (antibody) that binds to CRP in a calcium ion-dependent manner) mixed with 6.7 mM MES buffer (pH 5.0 (20 ° C.)) at a concentration of 0.1 g / dL 0.5098 mL was added and it stirred at 5 degreeC overnight.
  • MES buffer pH 5.0 (20 ° C.
  • antibody-2 immobilized latex particle suspension This was designated as antibody-2 immobilized latex particle suspension.
  • B Preparation of antibody-4-immobilized latex particle suspension As described in (b) of (2) of Example 3 above, antibody-4 (binding to CRP independent of calcium ions) 0.036% suspension of latex particles on which antibody was immobilized) was prepared, and this was designated as antibody-4 immobilized latex particle suspension.
  • C Preparation of Second Reagent [Antibody-2] 5 mL of the antibody-2 immobilized latex particle suspension prepared in (a) above and 5 mL of 0.05% sodium azide aqueous solution were mixed. A suspension containing 0.060% “latex particles immobilized with antibody-2 (an antibody that binds to CRP in a calcium ion-dependent manner)” was prepared.
  • second reagent [antibody-2] This was designated as a second reagent [antibody-2].
  • second reagent [antibody-4] 5 mL of the antibody-4-immobilized latex particle suspension prepared in (b) above and 5 mL of 0.05% aqueous sodium azide solution were mixed. A suspension containing 0.018% of “antibody-4 (an antibody that binds to CRP in a calcium ion-independent manner)” was prepared. This was designated as a second reagent [antibody-4].
  • Table 4 and Fig. 7 show the absorbance difference obtained by measuring CRP in the sample in (1).
  • the horizontal axis represents the CRP concentration (mg / dL) in the sample, and the vertical axis represents the value of absorbance difference obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • “ ⁇ ” indicates a measurement result (absorbance difference value) when “second reagent [antibody-2]” is used as the second reagent, and “ ⁇ ” indicates “second reagent”.
  • the anti-CRP antibody of the “carrier (latex particles) on which the anti-CRP antibody is immobilized” to be contained in the CRP measurement reagent in the sample is “calcium ion-dependent”
  • the above-mentioned “antibody-2” which is a specific binding substance (antibody) that binds to CRP ”and the“ antibody ”which is a“ specific binding substance (antibody) that binds to CRP independently of calcium ions ” -4 ”(when the second reagent is“ second reagent [antibody-2 / antibody-4] ”) the CRP in the sample is measured at a low concentration to a high concentration. It can be seen that the measurement range has expanded. That is, it was confirmed that the measurement method and the measurement reagent can accurately measure CRP in a wide range of concentrations from low concentration to high concentration.
  • Latex particles immobilized with antibody (antibody-3) that binds to CRP in a calcium ion-dependent manner, and latex particles immobilized with antibody (antibody-4) that binds to CRP in a calcium ion-independent manner The CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed. 1.
  • Reagent (1) 1st reagent 100% tris (hydroxymethyl) aminomethane containing 1% (w / v) BSA, 2M sodium chloride, 0.2mM calcium chloride dihydrate and 0.05% sodium azide -A hydrochloric acid buffer (pH 8.0 (20 ° C)) was prepared and used as the first reagent.
  • Antibody-3 [specific binding substance that binds to CRP in a calcium ion-dependent manner (antibody)] mixed with 6.7 mM MES buffer (pH 5.0 (20 ° C.)) at a concentration of 0.1 g / dL 0.5098 mL was added and it stirred at 5 degreeC overnight. Next, after removing the supernatant by centrifugation, 100 mM glycine buffer solution (pH 9.5 (20 ° C.) containing 1.0% BSA) is added to the precipitate and suspended, and the mixture is stirred at room temperature for 30 minutes to block. Processed.
  • the precipitate was recovered by centrifugation, and then suspended in a 0.05% aqueous sodium azide solution so that the absorbance at a wavelength of 585 nm was 9.5 OD.
  • This was diluted with a 0.05% aqueous sodium azide solution to prepare a 0.120% suspension of latex particles on which antibody-3 (an antibody that binds to CRP in a calcium ion-dependent manner) was immobilized. This was designated as an antibody-3 immobilized latex particle suspension.
  • Table 5 and Fig. 8 show the absorbance difference obtained by measuring CRP in the sample in (1).
  • the abscissa indicates the CRP concentration (mg / dL) in the sample, and the ordinate indicates the value of absorbance difference obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • “ ⁇ ” indicates a measurement result (absorbance difference value) when “second reagent [antibody-3]” is used as the second reagent, and “ ⁇ ” indicates “second reagent”.
  • the CRP in the sample is highly sensitive when it is in the low concentration range, but the medium concentration range to the high concentration range. It can be seen that the measurement does not have quantitative measurement.
  • the anti-CRP antibody of “carrier (latex particles) immobilized with anti-CRP antibody” contained in the CRP measurement reagent in the sample is “calcium ion-dependent”.
  • Antibody-5 Mouse anti-human CRP monoclonal antibody [clone: CRB-028] (Japan Biotest Laboratories) (4) Preparation of antibody sample (a) Calcium ion-containing anti-CRP antibody sample
  • Antibody-5 (anti-CRP antibody) of (3) above is diluted with the diluent A prepared in (1) above, and anti-CRP antibody A calcium ion-containing anti-CRP antibody sample having a concentration of 0.010 ⁇ g / mL, 0.10 ⁇ g / mL, 1.0 ⁇ g / mL, 10.0 ⁇ g / mL, or 100.0 ⁇ g / mL was prepared.
  • the diluent A prepared in the above (1) was used as a calcium ion-containing anti-CRP antibody sample having an anti-CRP antibody concentration of 0 ⁇ g / mL.
  • Antibody-5 (anti-CRP antibody) of (3) above is diluted with diluent B prepared in (2) above, and the concentration of anti-CRP antibody is 0.010 ⁇ g / mL EDTA-containing anti-CRP antibody samples of 0.10 ⁇ g / mL, 1.0 ⁇ g / mL, 10.0 ⁇ g / mL, or 100.0 ⁇ g / mL were prepared.
  • the diluent B prepared in the above (2) was used as an EDTA-containing anti-CRP antibody sample having an anti-CRP antibody concentration of 0 ⁇ g / mL. 3. Measurement by ELISA method (1) Measurement (b) Washing was performed by adding 400 ⁇ L of the washing solution prepared in (2) above to each well of the CRP-immobilized plate prepared in (1) above. This washing was performed 5 times in total. (B) Thereafter, for antibody-5 (anti-CRP antibody) prepared in (2) of (4) above, the concentration of the anti-CRP antibody was 0 ⁇ g / mL, 0.010 ⁇ g / mL, 0.10 ⁇ g / mL.
  • the binding property of the anti-CRP antibody to the calcium-binding CRP immobilized in each well is tested.
  • C Thereafter, the calcium ion-containing anti-CRP antibody sample in each well of the CRP-immobilized plate is removed by aspiration, and the washing solution prepared in (1) above is added to each well in an amount of 400 ⁇ L per well. This was washed a total of 5 times.
  • D Next, 50 ⁇ L of the peroxidase-labeled antibody prepared in (1) above was added to each well of the CRP-immobilized plate and reacted at 37 ° C. for 1 hour.
  • each well of the CRP-immobilized plate was washed by adding 400 ⁇ L of the washing solution prepared in (1) above per well, and this washing was performed 5 times in total.
  • F 100 ⁇ L of the color developing solution prepared in (1) above was added to each well of the CRP-immobilized plate and allowed to react at room temperature for 30 minutes.
  • G the absorbance at 415 nm of the reaction solution in each well of the CRP-immobilized plate was measured using a microplate reader (BioRad; Model 3550).
  • the measured value (absorbance) of the calcium ion-containing anti-CRP antibody sample having an anti-CRP antibody concentration of 0 ⁇ g / mL was subtracted to determine the value of the absorbance difference.
  • the calcium ions bound to the CRP immobilized in each well of the CRP-immobilized plate by the addition and contact of the EDTA-containing / anti-CRP antibody sample were:
  • the CRP immobilized in each of the wells by binding with EDTA ⁇ 2Na is a calcium non-binding CRP. Therefore, at this time, the binding property of the anti-CRP antibody to the calcium non-binding CRP immobilized in each well is tested.
  • the antibody-5 binds to almost the same extent as both calcium-bound CRP and calcium-unbound CRP. From this, it can be determined that the antibody-5 is a “specific binding substance (antibody) that binds to CRP independent of calcium ions”.
  • Example 2 Except that the procedure is as described in Example 2 (1) (2) (A) to prepare a 0.060% suspension of latex particles immobilized with antibody-5. did. This was designated as a second reagent [antibody-5]. 2. Sample (1) Preparation of Sample Diluent A sample diluent was prepared as described in 2 (1) of Example 2. (2) Preparation of Samples As described in 2 (2) of Example 2, the following samples were prepared. (A) Sample 1: 0 mg / dL (B) Sample 2: 0.5 mg / dL (C) Sample 3: 2.0 mg / dL (D) Sample 4: 6.0 mg / dL (E) Sample 5: 18.0 mg / dL (F) Sample 6: 30.0 mg / dL 3.
  • Measurement of CRP in sample (1) Measurement procedure (A) Measurement was performed using a Hitachi-7180 type automatic analyzer (manufactured by Hitachi, Ltd.). First, 3 ⁇ L of Sample 1, Sample 2, Sample 3, Sample 4, Sample 5, or Sample 6 of (2) above was added to a measurement cell (cuvette). Next, 100 ⁇ L of the first reagent (1) was added to these measurement cells (cuvettes) and mixed. These measurement cells (cuvettes) were allowed to stand at 37 ° C. (B) At 4 minutes and 34 seconds (16th point) after the addition of the first reagent, the liquid mixture in the measurement cell (cuvette) is further added to the second reagent of the above (2) [ 100 ⁇ L of Antibody-5] was added and mixed.
  • the horizontal axis represents the CRP concentration (mg / dL) in the sample, and the vertical axis represents the value of absorbance difference obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • ⁇ indicates a measurement result (absorbance difference value) when “second reagent [antibody-5]” is used as the second reagent. 4). Discussion From Table 7 and FIG. 10, “anti-CRP antibody binding to CRP is independent of calcium ion” as an anti-CRP antibody of “carrier (latex particle) on which anti-CRP antibody is immobilized” contained in a CRP measurement reagent in a sample.
  • the present invention comprising latex particles immobilized with an antibody (antibody-1) that binds to CRP in a calcium ion-dependent manner and latex particles immobilized with an antibody (antibody-4) that binds to a CRP in a calcium ion-independent manner.
  • the CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed.
  • Measurement reagent (1) 1st reagent The 1st reagent was prepared as the description of 1 of said Example 3 (1).
  • the abscissa indicates the CRP concentration (mg / dL) in the sample, and the ordinate indicates the value of absorbance difference obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • “ ⁇ ” indicates a measurement result (absorbance difference value) when “second reagent [antibody-1]” is used as the second reagent, and “ ⁇ ” indicates “second reagent”.
  • the measurement results (absorbance difference values) when using the second reagent [antibody-4] are shown, and “ ⁇ ” uses “second reagent [antibody-1 / antibody-4]” as the second reagent.
  • the measurement results (absorbance difference values) are shown. 4).
  • the “calcium ion” is used as an anti-CRP antibody of a “carrier (latex particle) on which an anti-CRP antibody is immobilized” to be contained in a CRP measurement reagent in a sample.
  • antibody-1 which is a specific binding substance (antibody) that binds to CRP in a dependent manner
  • second reagent is “second reagent [antibody-1]”
  • the sensitivity is low when the CRP in the sample is in the low concentration range, the sensitivity is high in the medium concentration range to the high concentration range and has a quantitative property of measurement.
  • an anti-CRP antibody of “carrier (latex particles) on which anti-CRP antibody is immobilized” to be contained in a CRP measurement reagent in a sample “specific binding to CRP in a calcium ion-dependent manner”
  • antibody-1 which is a “binding substance (antibody)”
  • antibody-4 which is a “specific binding substance (antibody) that binds to CRP in a calcium ion-independent manner” are used in combination.
  • the second reagent is “second reagent [antibody-1 / antibody-4]”
  • the measurement range should expand from a low concentration to a high concentration in the measurement of CRP in the sample. I understand. That is, it was confirmed that the measurement method and the measurement reagent can accurately measure CRP in a wide range of concentrations from low concentration to high concentration.
  • the present invention comprising latex particles immobilized with an antibody (antibody-2) that binds to CRP in a calcium ion-dependent manner and latex particles immobilized with an antibody (antibody-4) that binds to a CRP in a calcium ion-independent manner.
  • the CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed.
  • Measurement Reagent (1) First Reagent As described in Example 4, 1 (1), a first reagent was prepared.
  • Second Reagent (a) Antibody-2 Immobilized Latex Particle Suspension As described in Example 2, 1 (2) (a), antibody-2 immobilized latex particle suspension A liquid was prepared. (B) Preparation of Antibody-4 Immobilized Latex Particle Suspension Antibody-4 immobilized latex particle suspension was prepared as described in (2) of (2) of Example 4 above. (C) Preparation of Second Reagent [Antibody-2] The second reagent [Antibody-2] was prepared as described in Example 4, 1 (2) (c). (D) Preparation of Second Reagent [Antibody-4] As described in Example 2, 1 (2) (d), a second reagent [Antibody-4] was prepared.
  • the horizontal axis represents the CRP concentration (mg / dL) in the sample, and the vertical axis represents the absorbance difference value obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • “ ⁇ ” indicates a measurement result (absorbance difference value) when “second reagent [antibody-2]” is used as the second reagent, and “ ⁇ ” indicates “second reagent”.
  • the measurement results (absorbance difference values) when using the second reagent [antibody-4] are shown, and “ ⁇ ” uses “second reagent [antibody-2 / antibody-4]” as the second reagent.
  • the measurement results (absorbance difference values) are shown. 4).
  • the “calcium ion” is used as an anti-CRP antibody of a “carrier (latex particle) on which an anti-CRP antibody is immobilized” to be contained in a CRP measurement reagent in a sample.
  • antibody-2 which is a specific binding substance (antibody) that binds to CRP in a dependent manner
  • second reagent is “second reagent [antibody-2]”
  • the sensitivity is low when the CRP in the sample is in the low concentration range, the sensitivity is high in the medium concentration range to the high concentration range and has a quantitative property of measurement.
  • an anti-CRP antibody of “carrier (latex particles) on which anti-CRP antibody is immobilized” to be contained in a CRP measurement reagent in a sample “specific binding to CRP in a calcium ion-dependent manner”
  • antibody-2 which is a “binding substance (antibody)”
  • antibody-4 which is a “specific binding substance (antibody) that binds to CRP in a calcium ion-independent manner” are used in combination.
  • the second reagent is “second reagent [antibody-2 / antibody-4]”
  • the measurement range should expand from a low concentration to a high concentration in the measurement of CRP in the sample. I understand. That is, it was confirmed that the measurement method and the measurement reagent can accurately measure CRP in a wide range of concentrations from low concentration to high concentration.
  • Samples were performed as described in 2 (1) and (2) of Example 3 to prepare samples of the following CRP concentrations.
  • A Sample 1: 0 mg / dL
  • B Sample 2: 0.5 mg / dL
  • C Sample 3: 2.0 mg / dL
  • D Sample 4: 6.0 mg / dL
  • E Sample 5: 18.0 mg / dL
  • F Sample 6: 30.0 mg / dL 3.
  • the horizontal axis represents the CRP concentration (mg / dL) in the sample, and the vertical axis represents the value of the absorbance difference obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • “ ⁇ ” indicates a measurement result (absorbance difference value) when “second reagent [antibody-3]” is used as the second reagent, and “ ⁇ ” indicates “second reagent”.
  • the measurement results (absorbance difference values) when using the second reagent [antibody-4] are shown, and “ ⁇ ” used “second reagent [antibody-3 / antibody-4]” as the second reagent.
  • the measurement results (absorbance difference values) are shown. 4).
  • an anti-CRP antibody of “carrier (latex particle) on which anti-CRP antibody is immobilized” to be contained in a CRP measurement reagent in a sample “specific binding to CRP in a calcium ion-dependent manner”
  • antibody-3 which is a “binding substance (antibody)”
  • antibody-4 which is a “specific binding substance (antibody) that binds to CRP independently of calcium ions” are used in combination.
  • the second reagent is “second reagent [antibody-3 / antibody-4]”
  • the measurement range should be expanded from a low concentration to a high concentration in the measurement of CRP in the sample. I understand. That is, it was confirmed that the measurement method and the measurement reagent can accurately measure CRP in a wide range of concentrations from low concentration to high concentration.
  • the present invention comprising latex particles immobilized with an antibody (antibody-1) that binds to CRP in a calcium ion-dependent manner and latex particles immobilized with an antibody (antibody-5) that binds to a CRP in a calcium ion-independent manner.
  • the CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed.
  • Measurement reagent (1) 1st reagent The 1st reagent was prepared as the description of 1 of said Example 3 (1).
  • the measurement range should expand from a low concentration to a high concentration in the measurement of CRP in the sample. I understand. That is, it was confirmed that the measurement method and the measurement reagent can accurately measure CRP in a wide range of concentrations from low concentration to high concentration.
  • the present invention comprising latex particles to which an antibody that binds to CRP in a calcium ion-dependent manner (antibody-2) is immobilized, and latex particles to which an antibody that binds to CRP in a calcium ion-independent manner (antibody-5) is immobilized.
  • the CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed.
  • Measurement reagent (1) 1st reagent The 1st reagent was prepared as the description of 1 of said Example 3 (1).
  • Example 2 Second reagent
  • (b) Preparation of suspension of antibody-2 immobilized latex particles In place of antibody-1, antibody-2 (calcium ion-dependent) of (b) in (3) of Example 1-2
  • the antibody-2-immobilized latex particle suspension was prepared as described in Example 1, 1 (2) (b) except that the antibody binding to CRP was used.
  • (B) Preparation of antibody-5-immobilized latex particle suspension In place of antibody-4, antibody-5 (antibody binding to CRP in a calcium ion-independent manner) of Example 2-2 (3) is used. Otherwise, an antibody-5-immobilized latex particle suspension was prepared as described in 1 (2) (b) of Example 3 above.
  • FIG. 15 show the absorbance difference obtained by measuring CRP in the sample in (1).
  • the horizontal axis represents the CRP concentration (mg / dL) in the sample, and the vertical axis represents the value of the absorbance difference obtained by measurement [absorbance difference ⁇ 10,000] (main wavelength 570 nm, subwavelength 800 nm. ).
  • “ ⁇ ” indicates a measurement result (absorbance difference value) when “second reagent [antibody-2]” is used as the second reagent, and “ ⁇ ” indicates “second reagent”.
  • the measurement results when using the second reagent [antibody-5] are shown (absorbance difference values).
  • the present invention comprising latex particles to which an antibody that binds to CRP in a calcium ion-dependent manner (antibody-3) is immobilized, and latex particles to which an antibody that binds to CRP in a calcium ion-independent manner (antibody-5) is immobilized.
  • the CRP in the sample was measured using the CRP measurement reagent, and the effect was confirmed.
  • Measurement reagent (1) 1st reagent The 1st reagent was prepared as the description of 1 of said Example 3 (1).
  • Example 2 Second Reagent
  • the antibody-3-immobilized latex particle suspension was prepared as described in Example 1 (2) (b) except that the antibody binding to CRP was used.
  • antibody-3 which is a “specific binding substance (antibody) that binds to CRP in a dependent manner” (when the second reagent is “second reagent [antibody-3]”)
  • the sensitivity is low when the CRP in the sample is in the low concentration range, the sensitivity is high in the medium concentration range to the high concentration range and has a quantitative property of measurement.
  • the measurement range should be expanded from a low concentration to a high concentration in the measurement of CRP in the sample. I understand. That is, it was confirmed that the measurement method and the measurement reagent can accurately measure CRP in a wide range of concentrations from low concentration to high concentration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau procédé de mesure et un réactif de mesure pour mesurer la protéine C-réactive dans un échantillon en mesurant un agrégat complexe formé par une réaction de liaison spécifique entre la protéine C-réactive et une substance de liaison spécifique qui se lie à la protéine C-réactive et est fixée à un support. Le procédé et le réactif de mesure permettent que la plage de mesure soit étendue de faibles concentrations à des concentrations élevées et permettent que la concentration de la protéine C-réactive soit mesurée précisément dans une large plage de faibles concentrations à des concentrations élevées. Pour mesurer la protéine C-réactive dans un échantillon, une substance de liaison spécifique qui se lie à la protéine C-réactive de manière dépendante des ions calcium et une substance de liaison spécifique qui se lie à la protéine C-réactive de manière indépendante des ions calcium sont fixées à un support, et un agrégat complexe comprenant lesdites substances de liaison spécifique et la protéine C-réactive, qui est formé par ladite réaction de liaison spécifique entre lesdites substances de liaison spécifique fixées au support et la protéine C-réactive contenue dans l’échantillon, est mesuré.
PCT/JP2009/069898 2008-11-18 2009-11-18 Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon WO2010058860A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010539268A JP5807300B2 (ja) 2008-11-18 2009-11-18 試料中のｃ反応性蛋白質の測定方法及び測定試薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008318960 2008-11-18
JP2008-318960 2008-11-18

Publications (1)

Publication Number Publication Date
WO2010058860A1 true WO2010058860A1 (fr) 2010-05-27

Family

ID=42198299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/069898 WO2010058860A1 (fr) 2008-11-18 2009-11-18 Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon

Country Status (2)

Country Link
JP (1) JP5807300B2 (fr)
WO (1) WO2010058860A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012133782A1 (fr) * 2011-03-30 2012-10-04 中外製薬株式会社 Rétention de molécules de liaison à l'antigène dans le plasma sanguin et procédé de modification du caractère immunogène
WO2013046722A1 (fr) * 2011-09-30 2013-04-04 中外製薬株式会社 Bibliothèque de molécules de liaison dépendant de la concentration ionique
WO2013047729A1 (fr) * 2011-09-30 2013-04-04 中外製薬株式会社 Molécule de liaison d'un antigène induisant une réponse immunitaire pour cibler l'antigène
WO2013081143A1 (fr) * 2011-11-30 2013-06-06 中外製薬株式会社 Support contenant des médicaments dans une cellule pour former un complexe immunitaire
WO2013180201A1 (fr) * 2012-05-30 2013-12-05 中外製薬株式会社 Molécule de liaison d'antigène supprimant un antigène associé
CN103703129A (zh) * 2011-03-30 2014-04-02 中外制药株式会社 改变抗原结合分子的血浆中滞留性和免疫原性的方法
JPWO2012133782A1 (ja) * 2011-02-25 2014-07-28 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JP2018058891A (ja) * 2011-09-30 2018-04-12 中外製薬株式会社 抗原の消失を促進する抗原結合分子
JP2018173429A (ja) * 2018-08-20 2018-11-08 積水メディカル株式会社 ラテックス免疫凝集法における測定誤差低減方法
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
US10738111B2 (en) 2014-12-19 2020-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
JP2020134349A (ja) * 2019-02-21 2020-08-31 デンカ株式会社 ラテックス凝集法による目的物質の測定方法、およびその試薬
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04505857A (ja) * 1989-06-27 1992-10-15 ラッシュ―プレズビティリアン―セント　ルークス　メディカル　センター Ｃ反応性蛋白質に対するモノクローナル抗体
JPH11108929A (ja) * 1997-08-11 1999-04-23 F Hoffmann La Roche Ag 微粒子増強光分散凝集測定法
JP2000162212A (ja) * 1998-11-30 2000-06-16 Nitto Boseki Co Ltd Ｃｒｐ測定用プロゾーン現象抑制剤、ｃｒｐの測定方法、及びｃｒｐ測定試薬
JP2002040024A (ja) * 2000-03-31 2002-02-06 Ortho-Clinical Diagnostics Inc Ｃ反応性蛋白についての免疫測定
JP2004189665A (ja) * 2002-12-11 2004-07-08 Matsushita Electric Ind Co Ltd 抗ｃ反応性タンパク質抗体、この抗体を用いたバイオセンサ、この抗体の作製方法、及びこの抗体を用いた免疫測定方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04505857A (ja) * 1989-06-27 1992-10-15 ラッシュ―プレズビティリアン―セント　ルークス　メディカル　センター Ｃ反応性蛋白質に対するモノクローナル抗体
JPH11108929A (ja) * 1997-08-11 1999-04-23 F Hoffmann La Roche Ag 微粒子増強光分散凝集測定法
JP2000162212A (ja) * 1998-11-30 2000-06-16 Nitto Boseki Co Ltd Ｃｒｐ測定用プロゾーン現象抑制剤、ｃｒｐの測定方法、及びｃｒｐ測定試薬
JP2002040024A (ja) * 2000-03-31 2002-02-06 Ortho-Clinical Diagnostics Inc Ｃ反応性蛋白についての免疫測定
JP2004189665A (ja) * 2002-12-11 2004-07-08 Matsushita Electric Ind Co Ltd 抗ｃ反応性タンパク質抗体、この抗体を用いたバイオセンサ、この抗体の作製方法、及びこの抗体を用いた免疫測定方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAMI SHIIHA (KONO) ET AL.: "Ko-CRP Monoclonal Kotai o Mochiita Slide Gyoshu Hanno ni yoru Kecchu CRP no Sokutei", BULLETIN OF THE OGATA INSTITUTE FOR MEDICAL AND CHEMICAL RESEARCH, vol. 1991, 1991, pages 1 - 6 *
TAKAHIRO HAMAZAKI: "EDTA Sonzai Ji no Shihan Ko Kessei no CRP eno Ketsugo Kassei no Teika", THE JAPANESE JOURNAL OF CLINICAL PATHOLOGY, vol. 32, no. 2, 1984, pages 223 - 224 *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JPWO2012133782A1 (ja) * 2011-02-25 2014-07-28 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
US11718678B2 (en) 2011-02-25 2023-08-08 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
US10618965B2 (en) 2011-02-25 2020-04-14 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
JP6074360B2 (ja) * 2011-02-25 2017-02-01 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
CN103703129A (zh) * 2011-03-30 2014-04-02 中外制药株式会社 改变抗原结合分子的血浆中滞留性和免疫原性的方法
WO2012133782A1 (fr) * 2011-03-30 2012-10-04 中外製薬株式会社 Rétention de molécules de liaison à l'antigène dans le plasma sanguin et procédé de modification du caractère immunogène
JP6998748B2 (ja) 2011-09-30 2022-01-18 中外製薬株式会社 抗原の消失を促進する抗原結合分子
CN103975060B (zh) * 2011-09-30 2021-04-13 中外制药株式会社 离子浓度依赖性结合分子文库
WO2013046722A1 (fr) * 2011-09-30 2013-04-04 中外製薬株式会社 Bibliothèque de molécules de liaison dépendant de la concentration ionique
US11827699B2 (en) 2011-09-30 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities
JP2018058891A (ja) * 2011-09-30 2018-04-12 中外製薬株式会社 抗原の消失を促進する抗原結合分子
US10024867B2 (en) 2011-09-30 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
JP2018150378A (ja) * 2011-09-30 2018-09-27 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
WO2013047729A1 (fr) * 2011-09-30 2013-04-04 中外製薬株式会社 Molécule de liaison d'un antigène induisant une réponse immunitaire pour cibler l'antigène
US10253100B2 (en) 2011-09-30 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
JPWO2013046722A1 (ja) * 2011-09-30 2015-03-26 中外製薬株式会社 イオン濃度依存性結合分子ライブラリ
CN110627902A (zh) * 2011-09-30 2019-12-31 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
CN110655578A (zh) * 2011-09-30 2020-01-07 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
CN110680920A (zh) * 2011-09-30 2020-01-14 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
US10556949B2 (en) 2011-09-30 2020-02-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
JP7029355B2 (ja) 2011-09-30 2022-03-03 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
JPWO2013047729A1 (ja) * 2011-09-30 2015-03-26 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
JP2020079296A (ja) * 2011-09-30 2020-05-28 中外製薬株式会社 抗原の消失を促進する抗原結合分子
CN103975060A (zh) * 2011-09-30 2014-08-06 中外制药株式会社 离子浓度依赖性结合分子文库
US11243210B2 (en) 2011-09-30 2022-02-08 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
JP2022000472A (ja) * 2011-09-30 2022-01-04 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
CN104093424A (zh) * 2011-09-30 2014-10-08 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
CN107287660A (zh) * 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
JP7441284B2 (ja) 2011-11-30 2024-02-29 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
CN113416256A (zh) * 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
CN104080909A (zh) * 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
JP2017171660A (ja) * 2011-11-30 2017-09-28 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
WO2013081143A1 (fr) * 2011-11-30 2013-06-06 中外製薬株式会社 Support contenant des médicaments dans une cellule pour former un complexe immunitaire
JP2020055872A (ja) * 2011-11-30 2020-04-09 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
US11820793B2 (en) 2011-11-30 2023-11-21 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013180201A1 (fr) * 2012-05-30 2013-12-05 中外製薬株式会社 Molécule de liaison d'antigène supprimant un antigène associé
JPWO2013180201A1 (ja) * 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10738111B2 (en) 2014-12-19 2020-08-11 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11454633B2 (en) 2014-12-19 2022-09-27 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
JP2018173429A (ja) * 2018-08-20 2018-11-08 積水メディカル株式会社 ラテックス免疫凝集法における測定誤差低減方法
JP7327944B2 (ja) 2019-02-21 2023-08-16 デンカ株式会社 ラテックス凝集法による目的物質の測定方法、およびその試薬
JP2020134349A (ja) * 2019-02-21 2020-08-31 デンカ株式会社 ラテックス凝集法による目的物質の測定方法、およびその試薬

Also Published As

Publication number Publication date
JP5807300B2 (ja) 2015-11-10
JPWO2010058860A1 (ja) 2012-04-19

Similar Documents

Publication Publication Date Title
JP5807300B2 (ja) 試料中のｃ反応性蛋白質の測定方法及び測定試薬
US9541564B2 (en) Reagent for assaying D-dimer and kit of reagent for assaying D-dimer
JP5147709B2 (ja) ヒトシスタチンｃを評価するための比濁イムノアッセイ
JP5199067B2 (ja) 免疫凝集反応試薬キット及び抗原の測定方法
JPH0736016B2 (ja) 免疫グロブリンの定量方法
JP5903381B2 (ja) 抗ｆｄｐモノクローナル抗体、それを用いたｆｄｐ測定用試薬及び試薬キット、並びにｆｄｐ測定方法
JP5984670B2 (ja) Ｆｄｐ測定用試薬及び試薬キット、並びに測定方法
TW201802472A (zh) 抗人類血紅素單株抗體或抗體套組、抗人類血紅素單株抗體固定化不可溶性載體粒子、及使用其等之測定試劑或測定方法
WO2016159015A1 (fr) Réactif et procédé de dosage de complexe thrombine-antithrombine
JP7421711B2 (ja) ロイシンリッチα２グリコプロテインの免疫測定方法及び測定試薬
CN109069600A (zh) Il-21抗体及其用途
JP4578401B2 (ja) 固定化抗体の製造方法
JP4458622B2 (ja) 免疫学的測定方法及び測定用試薬
JP7313659B2 (ja) 試料中のｈｍｇｂ１の測定方法及び測定試薬
JP4422291B2 (ja) ヒトメダラシンの免疫学的測定方法
JP2515533B2 (ja) 蛋白の定量方法
JP2004059477A (ja) 非グリコシル化ヘモグロビン、グリコシル化ヘモグロビンに特異的に結合するモノクローナル抗体、その製造方法、並びにそれを用いた非グリコシル化ヘモグロビン及びグリコシル化ヘモグロビンの測定方法
RU2262703C1 (ru) Способ получения контрольных образцов, используемых в иммуноферментном анализе
JP5824568B2 (ja) Ｄダイマー測定方法
JP2023097737A (ja) 試料中のｈｍｇｂ１の測定方法及び測定試薬、抗ｈｍｇｂ１抗体を固定化した担体の非特異的凝集の抑制方法並びに試料中のｈｍｇｂ１測定時の試薬ブランクの上昇の抑制方法
JP2024043214A (ja) イヌｈｅｒ２の検出方法
JP5750645B2 (ja) アレルギー疾患の検査方法
JP2003004748A (ja) 膵臓癌診断用試薬
JP2011117923A (ja) Ｓｃｃａ２濃度測定によるアレルギー疾患の検査方法
JPH11236399A (ja) モノクローナル抗体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827641

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010539268

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 09827641

Country of ref document: EP

Kind code of ref document: A1